•Infusion site extravasation injury is a rare but serious adverse event of tisotumab vedotin.•Central venous access device should be considered in patients with risk factors receiving antibody drug conjugate therapy.•Topical steroids may be used as part of supportive measures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490808 | PMC |
| http://dx.doi.org/10.1016/j.gore.2024.101525 | DOI Listing |
Publication Analysis
Top Keywords
extravasation injury
8
tisotumab vedotin
4
vedotin extravasation
4
injury patient
4
patient recurrent
4
recurrent cervical
4
cervical cancer
4
cancer •infusion
4
•infusion site
4
site extravasation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!